Tagged Pear Therapeutics

0

Healthcare companies pair up to work on digital solutions for schizophrenia and MS

A collaboration between healthcare solutions provider, Novartis, and Pear Therapeutics has been announced that aims to develop digital therapeutics for patients with schizophrenia and multiple sclerosis (MS). The companies will work together, drawing on Novartis’ expertise in biomedical research and clinical development and Pear Therapeutics’ experience in digital therapeutics design and implementation, to develop new treatments…

0

FDA selects companies for digital health pilot programme

Nine companies have been selected to participate in the FDA’s digital health software precertification pilot (FDA Pre-cert), to help advance digital health regulation in the US. During his keynote address at the AdvaMed MedTech Conference, FDA commissioner Scott Gottlieb announced which companies would be taking part in the pilot. He said: “Our method for regulating…

0

FDA approves app to treat substance use disorders

The FDA has approved the first mobile app to help treat substance use disorders. It is the first time the FDA has approved a prescription-only digital app which claims to help people with substance use disorders. The app, Reset, was developed by start-up Pear Therapeutics and uses cognitive behavioural therapy (CBT) to help treat patients…

© 2018 Rapid Life Sciences Ltd, a Rapid News Communications Group Company. All Rights Reserved.

Privacy policy

Terms and conditions